Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash from Financing Activities (2019 - 2025)

Biodesix (BDSX) has disclosed Cash from Financing Activities for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 1044.2% year-over-year to $1.7 million, compared with a TTM value of $16.4 million through Dec 2025, down 68.46%, and an annual FY2025 reading of $16.4 million, down 68.46% over the prior year.
  • Cash from Financing Activities was $1.7 million for Q4 2025 at Biodesix, down from $4.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $51.3 million in Q2 2024 and bottomed at -$4.4 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $7.9 million, with a median of $593500.0 recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 7861.51% in 2022, while the deepest fall reached 671.97% in 2022.
  • Year by year, Cash from Financing Activities stood at -$4.4 million in 2021, then skyrocketed by 1059.16% to $41.8 million in 2022, then plummeted by 48.08% to $21.7 million in 2023, then plummeted by 100.83% to -$181000.0 in 2024, then skyrocketed by 1044.2% to $1.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BDSX at $1.7 million in Q4 2025, $4.8 million in Q3 2025, and $9.8 million in Q2 2025.